Literature DB >> 34303844

Dry eye disease flares: A rapid evidence assessment.

Christopher E Starr1, Reza Dana2, Stephen C Pflugfelder3, Edward J Holland4, Steven Zhang5, Desiree Owen5, Kim Brazzell5.   

Abstract

PURPOSE: Characteristics of periodic flares of dry eye disease (DED) are not well understood. We conducted a rapid evidence assessment to identify evidence for and characteristics of DED flares.
METHODS: Literature searches were performed in Embase® via Ovid®, MEDLINE®, and PubMed®. Clinical trials and observational studies published 2009-2019 were included if they investigated patients aged ≥18 years with clinically diagnosed DED who experienced a flare, defined as a temporary or transient episode of increased ocular discomfort, typically lasting days to a few weeks. Triggers of flares, patient-reported outcomes (symptoms), clinician-measured outcomes (signs), and changes in tear molecules were captured.
RESULTS: Twenty-one publications that included 22 studies met inclusion criteria. Five observational studies described evidence of DED flares in daily life, 5 studies reported changes following cataract/refractive surgery in patients with preoperative DED, and 12 studies employed controlled environment (CE) models. Real-world triggers of DED flares included air conditioning, wind, reading, low humidity, watching television, and pollution. CE chambers (dry, moving air) and surgery also triggered DED flares. Exacerbations of symptoms and signs of DED, assessed through varied measures, were reported during flares. Across studies, matrix metalloproteinase-9 and interleukin-6 increased and epidermal growth factor decreased during DED flares.
CONCLUSIONS: Evidence from 22 studies identified triggers and characteristics of DED flares. Further research is needed to assist clinicians in early diagnosis and treatment of patients experiencing flares.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dry eye disease; Epidermal growth factor; Exacerbations; Flares; Interleukin-6; Matrix metalloproteinase-9; Ocular surface; Rapid evidence assessment; Signs; Symptoms

Mesh:

Year:  2021        PMID: 34303844     DOI: 10.1016/j.jtos.2021.07.001

Source DB:  PubMed          Journal:  Ocul Surf        ISSN: 1542-0124            Impact factor:   5.033


  4 in total

1.  Protective effects of low-molecular-weight components of adipose stem cell-derived conditioned medium on dry eye syndrome in mice.

Authors:  Yuan-Chieh Lee; Li-Yi Sun; Jia-Rong Zhang
Journal:  Sci Rep       Date:  2021-11-08       Impact factor: 4.379

2.  Advances in Dry Eye Disease Examination Techniques.

Authors:  Yaying Wu; Chunyang Wang; Xin Wang; Yujie Mou; Kelan Yuan; Xiaodan Huang; Xiuming Jin
Journal:  Front Med (Lausanne)       Date:  2022-01-25

3.  Real-World Effectiveness, Tolerability and Safety of Cyclosporine A 0.1% Cationic Emulsion in Severe Keratitis and Dry Eye Treatment.

Authors:  Gerd Geerling; Samer Hamada; Stefan Trocmé; Sten Ræder; Xiangjun Chen; Claudia Fassari; Ines Lanzl
Journal:  Ophthalmol Ther       Date:  2022-03-17

4.  Tear matrix metalloproteinase-9 levels may help to follow a ocular surface injury in lagophthalmic eyes.

Authors:  Marcela Minaříková; Zdeněk Fík; Josef Štorm; Kateřina Helisová; Květoslava Ferrová; Gabriela Mahelková
Journal:  PLoS One       Date:  2022-09-09       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.